Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 6,122 matching trials from the live ClinicalTrials.gov search.
Filters: "type 2 diabetes" Clear all
Completed Not applicable Interventional

Intensive Discharge Intervention in Diabetes

NCT02122926
View directory record Official record
Conditions
Type II Diabetes, Cardiovascular Disease
Interventions
Intensive discharge intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 16, 2026, 5:31 AM EDT
Completed No phase listed Observational

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

NCT04972721
View directory record Official record
Conditions
Overweight, Obesity
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
3,439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 16, 2026, 5:31 AM EDT
Recruiting Phase 2 Interventional

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

NCT07142252
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 16, 2026, 5:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Milk Fat Intake and Metabolic Health Markers

NCT02659748
View directory record Official record
Conditions
Insulin Sensitivity, Type 2 Diabetes
Interventions
Milk Fat, Control Fat
Dietary Supplement
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 16, 2026, 5:31 AM EDT
Not listed Early Phase 1 Interventional

Evaluating the Healing of Diabetic Foot Ulcers With Compounded Anti-Infective Irrigation Therapy

NCT05076955
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
vancomycin-tobramycin-itraconazole
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 16, 2026, 5:31 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

NCT04583514
View directory record Official record
Conditions
Overweight and Obesity, Metabolic Syndrome
Interventions
Control, Overfeeding
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 42 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00799006
View directory record Official record
Conditions
Overweight
Interventions
Placebo, PF-04620110
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

NCT03136484
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Semaglutide, Canagliflozin, Placebo (canagliflozin), Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
57
States / cities
Anaheim, California • La Mesa, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials

NCT00105352
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mixed Meal Tolerance Test, Glucagon Stimulation Test
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 16, 2026, 5:31 AM EDT
Recruiting Not applicable Interventional

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes, Diabetes, Autoimmune, Diabetes Mellitus, Diabetes Mellitus Type 2, Diabetes Mellitus, Type I, Diabetes, Type II, Diabetes, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus Type II, Diabetes Type 2 on Insulin
Interventions
Bionic Pancreas, Routine Care
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 5:31 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Low-dose IL-2 in Established T1D - The "PROREG" Study

NCT03243058
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Diabetes, Autoimmune
Interventions
ILT-101 (Aldesleukin; IL-2), Treatment-Placebo Arm, Placebo Arm
Biological · Other
Lead sponsor
Jay S. Skyler
Other
Eligibility
8 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 16, 2026, 5:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Community Based DPP Program for Hispanic/Latino Females

NCT04052815
View directory record Official record
Conditions
Pre Diabetes, Obesity
Interventions
Diabetes prevention program culturally tailored
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

This Study Assessed the Impact of Diet on Gastric Emptying Time and Metabolic Flexibility

NCT03630263
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, Appetitive Behavior
Interventions
Raw Corn Starch, No Raw Corn Starch
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

NCT01342484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo, BI1356 low dose, BI1356 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Antonio, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 16, 2026, 5:31 AM EDT
Terminated Not applicable Interventional Results available

Diabetes-Obstructive Sleep Apnea Treatment Trial

NCT01901055
View directory record Official record
Conditions
Type 2 Diabetes, Obstructive Sleep Apnea
Interventions
CPAP, Sham-CPAP, Diabetes Education
Device · Behavioral
Lead sponsor
Eileen R. Chasens
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
4
States / cities
Detroit, Michigan • Pittsburgh, Pennsylvania • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes

NCT02409329
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
REACH, Helpline and A1c results, REACH + FAMS
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 16, 2026, 5:31 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672
View directory record Official record
Conditions
Melanoma
Interventions
Fianlimab, Cemiplimab, Pembrolizumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

NCT04157751
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo to Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
30
States / cities
Los Angeles, California • Orange, California • Torrance, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 16, 2026, 5:31 AM EDT
Recruiting Early Phase 1 Interventional

GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

NCT06338553
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Semaglutide (Rybelsus®), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Not applicable Interventional Results available

Clinical Effectiveness of Body Fat Distribution Imaging in Real-World Practice: The BODY-REAL Study

NCT04763772
View directory record Official record
Conditions
Overweight and Obesity, PreDiabetes, Type 2 Diabetes, Cardiovascular Risk Factor
Interventions
Body Fat Distribution Imaging Report, Basic Weight Information, Patient Provided, Physician Provided
Diagnostic Test · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
35 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 16, 2026, 5:31 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control

NCT03227575
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Plymouth State University
Other
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Plymouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

NCT01713530
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Greenbrae, California • Mission Hills, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 16, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study With Albiglutide and Warfarin

NCT01147731
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
warfarin plus albiglutide
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 16, 2026, 5:31 AM EDT